Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  megestrol acetate
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-25 of 67 for your search:
Start Over
Phase III Randomized, Double-Blind Study of Megestrol vs Dronabinol vs Both in Patients with Cancer-Related Anorexia and Cachexia
Phase: Phase III
Type: Supportive care
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCCTG-959255, NCI-P96-0075
S9626: Megestrol in Treating Hot Flashes Following Treatment for Breast Cancer
Phase: Phase III
Type: Supportive care
Status: Completed
Age: Not specified
Sponsor: NCI, Other
Protocol IDs: CDR0000067962, S9626, NCI-P00-0159, U10CA037429, SWOG-S9626, NCT00005975
Comparison of Megestrol and/or Omega-3 Fatty Acid-Enriched Nutritional Supplement in Treating Patients With Cancer-Related Weight Loss and Lack of Appetite
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000069218, NCCTG-989255, CAN-NCIC-SC18, NCI-P02-0205, SC18, NCT00031707
Phase III Comparison of Megestrol vs Megestrol/Tamoxifen in Patients with Inoperable Metastatic or Recurrent Endometrial Cancer
Phase: Phase III
Type: Treatment
Status: Completed
Age: no age specified
Sponsor: NCI
Protocol IDs: EST-4882
Phase III MEG vs MEG/DES vs Stilphostrol vs STZ for Previously Irradiated Hormone-Refractory Metastatic Prostatic Carcinoma
Phase: Phase III
Type: Treatment
Status: Closed
Age: no age specified
Sponsor:
Protocol IDs: NPCTG-1600
Phase III Randomized Comparison of Megestrol Acetate vs Tamoxifen for Advanced Breast Cancer in Postmenopausal Patients
Phase: Phase III
Type: Treatment
Status: Closed
Age: no age specified
Sponsor:
Protocol IDs: GUMC-8683, NCI-V83-0295
Phase III Endocrine Therapy with MEG vs AGT/HC vs MEG plus AGT/HC in Postmenopausal Women with Disseminated, TMX-Refractory Breast Cancer
Phase: Phase III
Type: Treatment
Status: Completed
Age: postmenopausal
Sponsor: NCI
Protocol IDs: SWOG-8312
Phase III Randomized, Crossover Comparison of Megestrol Acetate vs Tamoxifen in Patients with Metastatic Breast Cancer
Phase: Phase III
Type: Treatment
Status: Closed
Age: no age specified
Sponsor:
Protocol IDs: POA-74183, WFU-74183, NCI-V83-0355
Phase III Randomized, Crossover Comparison of Megestrol Acetate vs Tamoxifen in Postmenopausal ER-Positive Women with Advanced Breast Cancer, with Megestrol Acetate in ER-Negative Patients
Phase: Phase III
Type: Treatment
Status: Closed
Age: no age specified
Sponsor: NCI
Protocol IDs: YALE-HIC-3042, NCI-T83-1271D, T83-1271
Phase III Randomized, Crossover Comparison of Megestrol Acetate vs Tamoxifen in Patients with Metastatic Breast Cancer, with Megestrol Acetate in ER-Negative Patients
Phase: Phase III
Type: Treatment
Status: Closed
Age: no age specified
Sponsor: NCI
Protocol IDs: DFCI-83049, NCI-T84-0246D, T84-0246
Phase III Comparison of High- vs Low-Dose MEG in Patients with Advanced Carcinoma of the Breast
Phase: Phase III
Type: Treatment
Status: Closed
Age: over 18
Sponsor:
Protocol IDs: POA-74285
Phase III Randomized Trial of Hormone Therapy with TMX vs MEG vs TMX plus MEG in Patients with Advanced Breast Cancer
Phase: Phase III
Type: Treatment
Status: Closed
Age: no age specified
Sponsor:
Protocol IDs: NEDH-D-83007, NCI-V85-0130
Phase III Prospective Randomized Study of Adjuvant Immunotherapy with High-Dose Recombinant IL-2/LAK Cells in Patients with Locally Advanced Renal Cell Carcinoma
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-86-C-157A, NCI-T86-0247N, T86-0247
Phase III Randomized Comparison of TMX vs High-Dose MEG in Patients with Progressive Metastatic Carcinoma of the Breast
Phase: Phase III
Type: Treatment
Status: Completed
Age: over 18
Sponsor: NCI
Protocol IDs: BGSM-74289, NCI-T89-0113D, T89-0113
Phase III L-PAM/5-FU/MEG Chemotherapy vs ADR/CTX/5-FU/MEG for Primary Stage III or IV Recurrent or Residual Endometrial Cancer
Phase: Phase III
Type: Treatment
Status: Completed
Age: no age specified
Sponsor: NCI
Protocol IDs: GOG-28, GOG-7741
Phase III Randomized, Double-Blind Comparison of CGS 16949A vs Megestrol Acetate in Postmenopausal Women Who Develop Recurrent Breast Cancer While on Hormone Therapy
Phase: Phase III
Type: Treatment
Status: Closed
Age: postmenopausal/over 18
Sponsor:
Protocol IDs: CG-CGS-16949A-03, NCI-V90-0170
Phase III Randomized, Double-Blind Comparison of CGS 16949A vs Megestrol Acetate in Postmenopausal Women with Recurrent Breast Cancer Following One Prior Hormone Regimen
Phase: Phase III
Type: Treatment
Status: Closed
Age: postmenopausal/over 18
Sponsor:
Protocol IDs: CG-CGS-16949A-06, NCI-V90-0171
Phase III Randomized Double-Blind Study of Postoperative Clinical Adjuvant Therapy with MEG vs Placebo in Patients with Poor-Prognosis Stage I/II Malignant Melanoma
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCCTG-897051, MAYO-897051, NCCTG-89-70-51
Phase III Double-Blind, Randomized Study of MEG vs Placebo Combined with EP (VP-16/CDDP) in Patients with Extensive Disease Small Cell Lung Cancer
Phase: Phase III
Type: Treatment
Status: Completed
Age: any age
Sponsor: NCI
Protocol IDs: NCCTG-892051, MAYO-892051, NCCTG-89-20-51
Phase III Randomized, Placebo-Controlled Study of MEG for the Control of Hot Flushes in Patients with Prostate Cancer (Summary Last Modified 03/93)
Phase: Phase III
Type: Supportive care
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCCTG-909255, MAYO-909255, NCI-P91-0025
Phase III Randomized Study of Megestrol Acetate vs Fluoxymesterone vs Dexamethasone for the Treatment of Cancer-Related and Cancer Treatment-Related Anorexia and Cachexia
Phase: Phase III
Type: Supportive care
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCCTG-919252, MAYO-919252, NCI-P92-0004
Start Over